Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Free Report) – Analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for shares of Molecular Partners in a research report issued on Tuesday, January 27th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($2.10) per share for the year. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.93) per share. HC Wainwright also issued estimates for Molecular Partners’ Q4 2025 earnings at ($0.40) EPS.
Several other research firms also recently commented on MOLN. JPMorgan Chase & Co. dropped their price objective on shares of Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Molecular Partners has an average rating of “Hold” and an average price target of $9.58.
Molecular Partners Trading Up 2.4%
MOLN opened at $4.25 on Thursday. Molecular Partners has a 12-month low of $3.36 and a 12-month high of $5.35. The firm has a 50 day moving average of $4.24 and a two-hundred day moving average of $3.95. The firm has a market capitalization of $171.62 million, a PE ratio of -2.21 and a beta of 1.07.
Molecular Partners (NASDAQ:MOLN – Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.05.
Molecular Partners Company Profile
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.
The company’s development pipeline spans infectious diseases, ophthalmology and oncology.
See Also
- Five stocks we like better than Molecular Partners
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- A U.S. “birthright” claim worth trillions – activated quietly
- The Crash Has Already Started (Most Just Don’t See It Yet)
- If You Keep Cash In A U.S. Bank Account… Read This NOW
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
